Clinical results show that raloxifene benefits heart and bone in postmenopausal women without increasing the risk of uterine cancer but its long-term effects are unknown.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hammond, G.B. Menopause and hormone replacement therapy: An overview. Obstet. Cynecol. 87, 2–15 (1995)
Sato, M., Rippy, M.K. & Bryant, H.U. Raloxifene, tamoxifen, nafoxidine or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10, 905–912 (1996)
Ward, R.L. et al. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner. 22, 87–94 (1993).
Black, L.J. et al. Raloxifene (LY1 39481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Gin. Invest. 93, 63–69 (1994).
Delmas, P.D. et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641–1647 (1997).
Scharf, M.B. et al. Effects of estrogen replacement therapy on rates of cyclic alternating patterns and hot-flush events during sleep in postmenopausal women: a pilot study. Clinical Therapeutics 19, 304–311 (1997).
Bergman, A., Karram, M.M. & Bhatia, N.N. Changes in urethral cytology following estrogen administration. Gynecologic & Obstetric Investigation 29, 211–213 (1990).
Henderson, V.W. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 48, 27–35 (1997)
Meisel, R.L. et al. Antagonism of sexual behavior in female rats by ventromedial hypothalamic implants of antiestrogen. Neuroendocrinology 45, 201–207 (1987).
Kuiper, G.G. & Gustafsson, J.-Å. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and antiestrogens. FEBS Letts. 410, 87–90 (1997).
Paech, K. et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP-1 sites). Science 277, 1508–1510 (1997).
Brzozowski, A.M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753–758 (1997)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gustafsson, JÅ. Raloxifene: Magic bullet for heart and bone?. Nat Med 4, 152–153 (1998). https://doi.org/10.1038/nm0298-152
Issue Date:
DOI: https://doi.org/10.1038/nm0298-152
This article is cited by
-
How were new medicines discovered?
Nature Reviews Drug Discovery (2011)
-
Applications of Binding Kinetics to Drug Discovery
Pharmaceutical Medicine (2008)